Asset Details
Do you wish to reserve the book?
Azilsartan Decreases Renal and Cardiovascular Injury in the Spontaneously Hypertensive Obese Rat
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Azilsartan Decreases Renal and Cardiovascular Injury in the Spontaneously Hypertensive Obese Rat
Do you wish to request the book?
Azilsartan Decreases Renal and Cardiovascular Injury in the Spontaneously Hypertensive Obese Rat
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Azilsartan Decreases Renal and Cardiovascular Injury in the Spontaneously Hypertensive Obese Rat
2014
Overview
Purpose
Angiotensin II type 1 receptor blockers (ARBs) are widely used in treating hypertension. In the present study, we tested the hypothesis that a novel ARB, azilsartan medoxomil (AZL-M) will prevent renal and cardiovascular injury in the spontaneously hypertensive obese rat (SHROB), a model of cardiometabolic syndrome.
Methods
Male SHROB were treated with vehicle or AZL-M orally for 56 days. Vehicle treated normotensive Wistar-Kyoto (WKY) rats served as controls. The effects of AZL-M on kidney injury, vascular endothelial and heart functions, lipid profile, and glucose tolerance were assessed.
Results
AZL-M demonstrated anti-hypertensive effects along with markedly improved vascular endothelial function in SHROB. In these rats, AZL-M demonstrates strong kidney protective effects with lower albuminuria and nephrinuria along with reduced tubular cast formation and glomerular injury. AZL-M treatment also improved left ventricular heart function, attenuated development of left ventricular hypertrophy, and reduced cardiac fibrosis in SHROB.
Conclusion
Overall, these findings demonstrate kidney and heart protective effects of AZL-M in SHROB, and these effects were associated with its ability to lower blood pressure and improve endothelial function.
Publisher
Springer US,Springer,Springer Nature B.V
Subject
/ Antihypertensive Agents - pharmacology
/ Antihypertensive Agents - therapeutic use
/ Arterial hypertension. Arterial hypotension
/ Benzimidazoles - pharmacology
/ Benzimidazoles - therapeutic use
/ Biological and medical sciences
/ Hypertrophy, Left Ventricular - blood
/ Hypertrophy, Left Ventricular - drug therapy
/ Hypertrophy, Left Ventricular - pathology
/ Male
/ Medicine
/ Mesenteric Arteries - drug effects
/ Mesenteric Arteries - physiology
/ Obesity
/ Oxadiazoles - therapeutic use
/ Pharmacology. Drug treatments
/ Protective Agents - pharmacology
